Kamada (KMDA) Operating Margin (2012 - 2026)
Kamada (KMDA) posted quarterly Operating Margin of 15.37% for Q1 2026, down 234.0% year-on-year from 11.47% in Q1 2025, and down 18.57% on a QoQ basis from 18.88% in Q4 2025.
Kamada (KMDA) Operating Margin (2012 - 2026) Analysis & Trends
Kamada (KMDA) has reported Operating Margin for 15 consecutive years, with 15.37% the latest figure, recorded in Q1 2026.
- Quarterly Operating Margin fell 234.0% year-over-year to 15.37% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 42.23% (up 4215.0% YoY) and the FY2025 annual result came in at 14.54%, up 208.0% from the prior year.
- Operating Margin slipped to 15.37% in Q1 2026 per KMDA's latest filing, from 18.88% in the prior quarter.
- Over the last five years, Operating Margin for KMDA reached as high as 11514.74% in Q3 2023 and fell as low as 9.72% in Q2 2022.
- A 5-year average of 689.27% and a median of 10.7% in 2024 frame the typical range for Operating Margin.
- Annual changes were most pronounced in 2023 — Operating Margin jumped 1150678 bps — and 2024, when it sank 1149127 bps.
- Year by year, Operating Margin stood at 8.84% in 2022, then declined by 14 bps to 7.62% in 2023, then jumped by 224 bps to 24.73% in 2024, then declined by 24 bps to 18.88% in 2025, then decreased by 19 bps to 15.37% in 2026.
- According to Business Quant data, Operating Margin over the past three periods registered 15.37%, 18.88%, and 26.21% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 16.37% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 36.83% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -38.02% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 41.69% |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -2.27% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 23.74% |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 21.23% |
| 10 | Kamada | 401.22 Mn | 328.07 Mn | 19.12 Mn | 15.37% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 15.37% |
| Dec 31, 2025 | 18.88% |
| Sep 30, 2025 | 26.21% |
| Jun 30, 2025 | 42.30% |
| Mar 31, 2025 | 17.71% |
| Dec 31, 2024 | 24.73% |
| Sep 30, 2024 | 23.47% |
| Jun 30, 2024 | 0.01% |
| Mar 31, 2024 | 10.70% |
| Dec 31, 2023 | 7.62% |
| Sep 30, 2023 | 11,514.74% |
| Jun 30, 2023 | 7.03% |
| Mar 31, 2023 | 0.94% |
| Dec 31, 2022 | 8.84% |
| Sep 30, 2022 | 7.95% |
| Jun 30, 2022 | -9.72% |
| Mar 31, 2022 | 0.88% |
| Dec 31, 2021 | -10.49% |
| Sep 30, 2021 | -3.49% |
| Jun 30, 2021 | 4.32% |